


Web Figure. Examples of determining index date for sustained eGFR <15 mL/min cohort



The Figure shows how the different components of the inclusion criteria relate to one another – and in particular, how the requirement for confirmed CKD (two measurements of eGFR <60 ml/min/1.73m² within a 90d period) relates to the requirement for sustained eGFR <15 ml/min/1.73m².

For example, the patient in the first row is not classified as having CKD until the measurement of eGFR=10 ml/min/1.73m² (because the measurements of 59 and 14 ml/min/1.73m² have occurred within a period of <90d). Since patients must be confirmed with CKD as well as having eGFR < 15 ml/min/1.73m² to be included in the study, this patient is not eligible until the measurement of 10 ml/min/1.73m² is recorded – and therefore, this date is used as the index date.

eGFR glomerular filtration rate estimated using the Chronic Kidney Disease Epidemiology Collaboration equation

Web Table. Percent initiating chronic RRT by important factors

Age	Heavy/severe proteinuria	Dementia	Metastatic cancer	Distance, km	Sex	In first year	Over full follow-up
≥70	N	Y	Y	>200	Female	0.9	3.2
≥70	N	Y	Y	≤50	Female	1.3	4.5
≥70	N	Y	N	>200	Female	1.5	5.2
≥70	N	Y	Y	>200	Male	2.0	6.7
≥70	N	Y	N	≤50	Female	2.2	7.4
≥70	N	N	Y	>200	Female	2.5	8.6
≥70	Y	Y	Y	>200	Female	2.8	9.3
50-69.9	N	Y	Y	>200	Female	2.8	9.4
≥70	N	Y	Y	≤50	Male	2.8	9.5
≥70	N	Y	N	>200	Male	3.2	10.8
50-69.9	N	Y	Y	>200	Male	3.3	11.2
≥70	N	N	Y	≤50	Female	3.6	12.2
≥70	Y	Y	Y	≤50	Female	4.0	13.2
50-69.9	N	Y	Y	≤50	Female	4.0	13.2
≥70	N	N	N	>200	Female	4.2	13.9
<50	N	Y	Y	>200	Female	4.3	14.2
≥70	Y	Y	N	>200	Female	4.5	15.0
50-69.9	N	Y	N	>200	Female	4.6	15.0
≥70	N	Y	N	≤50	Male	4.6	15.2
50-69.9	N	Y	Y	≤50	Male	4.8	15.7
≥70	N	N	Y	>200	Male	5.4	17.7
50-69.9	N	Y	N	>200	Male	5.5	17.9
≥70	Y	Y	Y	>200	Male	5.9	19.1
<50	N	Y	Y	>200	Male	6.0	19.5
≥70	N	N	N	≤50	Female	6.0	19.4
<50	N	Y	Y	≤50	Female	6.1	19.8
≥70	Y	Y	N	≤50	Female	6.5	20.9
50-69.9	N	Y	N	≤50	Female	6.5	20.9
<50	N	Y	N	>200	Female	7.0	22.4
≥70	Y	N	Y	>200	Female	7.6	24.2
50-69.9	N	N	Y	>200	Female	7.6	24.2
≥70	N	N	Y	≤50	Male	7.7	24.5
50-69.9	N	Y	N	≤50	Male	7.8	24.7
50-69.9	Y	Y	Y	>200	Female	8.2	39.3
≥70	Y	Y	Y	≤50	Male	8.3	26.3
<50	N	Y	Y	≤50	Male	8.5	26.8

Age	Heavy/severe proteinuria	Dementia	Metastatic cancer	Distance, km	Sex	In first year	Over full follow-up
≥70	N	N	N	>200	Male	8.8	27.6
50-69.9	N	N	Y	>200	Male	9.2	28.4
≥70	Y	Y	N	>200	Male	9.5	29.6
<50	N	Y	N	>200	Male	9.8	30.2
50-69.9	Y	Y	Y	>200	Male	9.9	30.4
<50	N	Y	N	≤50	Female	9.9	30.6
≥70	Y	N	Y	≤50	Female	10.8	32.8
50-69.9	N	N	Y	≤50	Female	10.8	32.9
<50	N	N	Y	>200	Female	11.6	35.0
50-69.9	Y	Y	Y	≤50	Female	11.6	35.2
≥70	Y	N	N	>200	Female	12.3	36.8
50-69.9	N	N	N	>200	Female	12.3	36.8
≥70	N	N	N	≤50	Male	12.4	37.2
<50	Y	Y	Y	>200	Female	12.5	37.4
50-69.9	N	N	Y	≤50	Male	12.8	38.2
50-69.9	Y	Y	N	>200	Female	13.3	26.0
≥70	Y	Y	N	≤50	Male	13.5	39.7
<50	N	Y	N	≤50	Male	13.8	40.5
50-69.9	Y	Y	Y	≤50	Male	13.9	40.7
50-69.9	N	N	N	>200	Male	14.6	42.5
≥70	Y	N	Y	>200	Male	15.7	44.9
50-69.9	Y	Y	N	>200	Male	15.8	45.2
<50	N	N	Y	>200	Male	16.0	45.7
<50	N	N	Y	≤50	Female	16.2	46.2
≥70	Y	N	N	≤50	Female	17.2	48.3
50-69.9	N	N	N	≤50	Female	17.2	48.4
<50	Y	Y	Y	>200	Male	17.3	48.6
<50	Y	Y	Y	≤50	Female	17.5	49.1
<50	N	N	N	>200	Female	18.5	51.1
50-69.9	Y	Y	N	≤50	Female	18.6	51.3
<50	Y	Y	N	>200	Female	19.9	54.0
50-69.9	N	N	N	≤50	Male	20.4	55.0
50-69.9	Y	N	Y	>200	Female	21.5	57.2
≥70	Y	N	Y	≤50	Male	21.8	57.6
50-69.9	Y	Y	N	≤50	Male	22.0	58.0
<50	N	N	Y	≤50	Male	22.2	58.5
<50	Y	Y	Y	≤50	Male	23.9	61.6

Age	Heavy/severe proteinuria	Dementia	Metastatic cancer	Distance, km	Sex	In first year	Over full follow-up
≥70	Y	N	N	>200	Male	24.6	62.8
<50	N	N	N	>200	Male	25.2	63.7
<50	N	N	N	≤50	Female	25.5	64.3
50-69.9	Y	N	Y	>200	Male	25.6	64.0
<50	Y	Y	N	>200	Male	27.0	66.8
<50	Y	Y	N	≤50	Female	27.4	67.3
50-69.9	Y	N	Y	≤50	Female	29.5	70.5
<50	Y	N	Y	>200	Female	31.4	73.3
50-69.9	Y	N	N	>200	Female	33.1	75.5
≥70	Y	N	N	≤50	Male	33.4	75.9
<50	N	N	N	≤50	Male	34.1	76.8
50-69.9	Y	N	Y	≤50	Male	34.3	77.1
<50	Y	Y	N	≤50	Male	36.5	79.6
50-69.9	Y	N	N	>200	Male	38.4	81.7
<50	Y	N	Y	>200	Male	41.4	84.6
<50	Y	N	Y	≤50	Female	41.9	85.0
50-69.9	Y	N	N	≤50	Female	43.9	86.8
<50	Y	N	N	>200	Female	46.5	88.8
50-69.9	Y	N	N	≤50	Male	50.2	91.3
<50	Y	N	Y	≤50	Male	53.7	93.3
<50	Y	N	N	>200	Male	58.8	95.5
<50	Y	N	N	≤50	Female	59.4	95.7
<50	Y	N	N	≤50	Male	72.2	98.9

The table is shaded to illustrate the likelihood of initiating RRT (darker shading represents a lower likelihood).

RRT renal replacement therapy, CVD cerebrovascular disease, COPD chronic obstructive pulmonary disease, CHF congestive heart failure, MI myocardial infarction, PUD peptic ulcer disease PVD peripheral vascular disease

Adjusted for a population with the following characteristics: 3.3% Aboriginal, 4.6% income support, 15.4% rural, 47.6% diabetes, 90.3% hypertension, 19.6% non-metastatic cancer, 17.3% CVD, 34.0% COPD, 44.1% CHF, 3.2% mild liver disease, 1.2% moderate/severe liver disease, 22.0% MI, 2.5% paraplegia, 7.7% PUD, 15.6% PVD, 4.8% rheumatoid disease, 21.6% affective disorder, 4.4% psychotic disorder.